The aim of these experiments was to determine the contribution of leukocyte-derived iNOS to total iNOS expression induced by lipopolysaccharide (LPS). By transferring bone marrow between iNOS +/+ and iNOS -/-mice, we created chimeric mice in which iNOS expression was limited to either circulating leukocytes (leukocyte-iNOS mice) or parenchymal cells (parenchyma-iNOS mice). Analysis of congenic markers demonstrated that >95% of thymocytes in chimeric mice were of donor origin. Also, following LPS treatment, iNOS mRNA was detectable in blood from leukocyte-iNOS mice but not parenchyma-iNOS mice. Together these findings indicated that the host marrow had been replaced entirely by donor cells. In the lung, at least 50% of the LPS-induced iNOS mRNA was derived from leukocytes, and immunohistochemical analysis indicated that leukocytes were the main source of iNOS protein.
that this elevation in nitric oxide production occurs via induction of the inducible isoform of nitric oxide synthase, iNOS. This theory has been demonstrated by an absence of elevation in plasma nitrate/nitrite in iNOS-deficient (iNOS -/-) mice undergoing systemic inflammatory responses (6) .
iNOS-derived nitric oxide has been implicated as a detrimental mediator in the sepsis response. Some evidence indicates that production of high levels of nitric oxide by iNOS is a cause of sepsis-induced hypotension (3, 7) . Furthermore, nitric oxide is thought to interact with the superoxide anion to form the potentially damaging peroxynitrite molecule (8) . The formation of this molecule is attributable predominantly to leukocytes, which can produce substantial levels of both iNOS and reactive oxygen species (9) . In contrast, some evidence indicates that nitric oxide has beneficial effects in numerous models of tissue injury. iNOS has been shown to be protective in models of colonic inflammation (10, 11) , liver regeneration (12) , allograft arteriosclerosis (13) , experimental allergic encephalomyelitis (EAE) (14) , and traumatic brain injury (15) . However, it is conceivable that these protective effects apply only when the production of iNOS occurs in the absence of generation of reactive oxygen species, as these species can readily inactivate nitric oxide or, as already mentioned, potentially cause the generation of additional toxic molecules.
An aspect of iNOS function during sepsis that may be critical in determining the net effect of its activity is the type of cell in which it is expressed, that is, leukocyte vs. parenchymal cell. Indeed, a unique attribute of the inducible NOS isoform is that, in addition to tissue-resident leukocytes, a wide range of parenchymal cell types, including endothelial cells, hepatocytes, and smooth muscle cells, can express iNOS in response to appropriate stimulation (16) . Furthermore, even circulating leukocytes have been observed to express iNOS in both experimental models of sepsis, and sepsis patients (3, 17) . Circulating cells expressing iNOS have the potential to deliver a significant amount of iNOS-derived nitric oxide to any vascular bed in the circulation. Given these numerous potential cellular sources of iNOS, the role of nitric oxide derived from iNOS during endotoxemia may potentially depend on the type and location of the cells responsible for its production. Therefore, the aim of this study was to determine whether circulating leukocytes are a significant source of iNOS during the endotoxemic response. To examine this issue, we transferred bone marrow between iNOS -/-and wild-type (WT) mice to create chimeric mice that were capable of expressing iNOS either solely in the parenchymal compartment (parenchymaiNOS mice) or, conversely, only in leukocytes (leukocyte-iNOS mice). Analysis of tissues from these animals allowed an unambiguous determination of the relative contributions of parenchymal and bone marrow-derived cells to total iNOS expression during endotoxemia. In addition, plasma levels of the NOS byproduct nitrite were used as an index of enzymatic activity. Under the conditions studied here, it appeared that, in most tissues other than the lung, iNOS was derived predominantly from parenchymal cells. However, leukocyte-derived iNOS was a significant source in the lung, apparently because of the comparatively high level of leukocyte infiltration into this tissue.
MATERIALS AND METHODS

Animals
iNOS
-/-mice on a C57Bl/6 background were generously provided by Victor Laubach (University of Virginia, Charlottesville). These mice were originally generated by homologous recombination on a mixed C57Bl/6 × Sv129 background (18) . The mice used in this study were backcrossed to C57Bl/6 for 10 generations (19) , ensuring genetic identity between donor and recipient mice in bone marrow transfer studies. These mice express the congenic marker Thy 1.2 (CD90.2). For the bone marrow transfer studies, congenic WT C57Bl/6 mice expressing Thy 1.1 (CD90.1) were obtained from The Jackson Laboratories (Bar Harbor, Maine). All animals were housed under specific pathogen-free (SPF) conditions.
Production of iNOS-chimeric mice
Chimeric animals were produced as previously described (20) . Briefly, on the day of transfer, recipient mice received two radiation doses of 525 Rads, 3 h apart, from a 137 Cs source (Gammacell, Atomic Energy of Canada, Ottawa, ON, Canada). Bone marrow was harvested from femurs and tibias of donor mice under sterile conditions. Following final irradiation, 8 × 10 6 bone marrow cells were injected into the recipient via the tail vein. Chimeric mice were treated with neomycin in the drinking water for the first 2 weeks after bone marrow transfer and maintained under SPF conditions for 8 weeks to allow for bone marrow reconstitution. Bone marrow reconstitution was confirmed by staining isolated thymocytes for Thy 1.1 and Thy 1.2 (FITC-labeled HIS51 and PE-labeled 53-2.1, respectively, (BD Pharmingen, San Diego, CA) and analysis by two-color flow cytometry by using a FACScan (BD Biosciences Canada, Mississauga, ON).
Experimental Plan
Four groups of mice were examined. Two chimeric groups were created in which 1) WT bone marrow was transferred into iNOS -/-mice (leukocyte-iNOS), or 2) iNOS -/-bone marrow was transferred into WT mice (parenchyma-iNOS). These mice were compared with two groups of control mice in which either WT bone marrow was transferred into WT mice (WT-intact), or iNOS -/-bone marrow was transferred into iNOS -/-mice (iNOS -/-BMT ). All mice were treated with either 10 or 30 µg/kg LPS (i.v.), injected via the femoral vein under anesthesia. Mice were allowed to recover then were killed 4 h after LPS injection. The lungs, liver, colon, and cremaster muscles were removed for mRNA analysis and immunohistochemistry. For analysis of leukocyte mRNA, 500 µL of whole blood was removed via cardiac puncture by using ethylene diamine tetraacetate (EDTA) as an anticoagulant. In separate experiments, heparinized blood was collected for nitrite analysis. The thymus was removed for confirmation of bone marrow reconstitution.
RT-PCR analysis of iNOS mRNA
Tissue samples were rinsed with saline and immediately homogenized in Trizol (Gibco-BRL, Burlington, Ontario, Canada), and total RNA was extracted according to the manufacturers instructions (21) . The final RNA concentration was determined by absorbance by using a GeneQuant spectrophotometer (Pharmacia, Piscataway, NJ). Whole blood RNA was isolated by using Tri Reagant BD (Molecular Research Center, Inc., Cincinatti, OH) according to the manufacturer's instructions.The following reverse transcription (RT) and polymerase chain reaction (PCR) steps were performed as described by Wong et al. (22) . Briefly, complementary DNA (cDNA) was synthesized by RT of 2 µg of total RNA in a volume of 20 µL containing 1× PCR buffer (10 mM Tris-HCl, pH 9.0; 50 mM KCl; 1.5 mM MgCl); 1 mM each of dATP, dGTP, dCTP, and dTTP; 30 U of placental ribonuclease inhibitor (RNA guard, Pharmacia, Piscataway, NJ); 200 U of superscript reverse transcriptase (GIBCO-BRL); and 2000 pmol of random hexamer oligodeoxynucleotides (Pharmacia). Reactions were performed in a GeneAmp PCR System 2400 (Perkin Elmer, Boston, MA) for 10 min at 21 o C, 50 min at 42 o C, followed by a final heating step at 95 o C for 5 min to terminate the reaction.
We amplified 2 µL of this cDNA by PCR in a 50 µL reaction volume containing 1× PCR buffer, 80 µM of each deoxynucleotide, and 20 pmol of each specific 5' and 3' starter primers by using a GeneAmp PCR System 2400 (Perkin Elmer). The following primer sequences (5'→3') were used for iNOS: the sense TCA CTG GGA CAG CAC AGA AT and anti-sense TGA AGC CAT GAC CTT TCG CAT TAG CAT GG with a final PCR product size of 1422 base pairs (bp). GAPDH cDNA was co-amplified as an internal control by using the following primer sequences (5'→3'); sense CGG AGT CAA CGG ATT TGG TCG TAT and the antisense AGC CTT CTC CAT GGT GGT GAA GAC (22) with a final PCR product size of 302 bp. Two units of Taq DNA polymerase (Pharmacia) were added to each tube during the first denaturation step, and equal aliquots of secondary primer sets (20 pmol GAPDH) were added at the appropriate cycle number by the primer dropping method (22) . Each PCR cycle consisted of a heat-denaturation step at 94 o C for 1 min, a primer-annealing step at 55 o C for 30 s, and a polymerization step at 72 o C for 1 min. To ensure that PCR amplification was in the exponential range, cycle tests were performed for each tissue at each dose of LPS using samples taken from LPS-stimulated mice. Subsequently, identical cycle numbers were used for each group of tissues within the same LPS treatment group. Aliquots of PCR products, normalized to give equivalent signals from the GAPDH cDNA for each tissue, were electrophoresed through 2% agarose gels (Ultrapure, Pharmacia) containing 0.5 µg/mL of ethidium bromide. Gels were visualized under UV light and photographed with a Kodak digital camera (Kodak Canada, Vancouver, BC).
To provide a semiquantitative analysis of the RT-PCR data, digitized images of the gels were analyzed by using Scion Image software (Scion Corp., Frederick, MD). The band densities (B.D.) of iNOS and GAPDH bands were determined, and a ratio (B.D. iNOS RT-PCR product/B.D. GAPDH RT-PCR product) was determined (denoted Relative Units). Data were analyzed from 5-6 mice per group and were displayed as mean ± SEM.
Myeloperoxidase (MPO) measurements
Samples for MPO analysis were frozen in liquid nitrogen immediately after removal from the animal. Tissue MPO levels were determined by using a previously described dianisidine-H 2 O 2 technique following enzyme extraction by hexadecyl-trimethylammonium bromide (HTAB) (23) . Using 96-well plates, we determined the change in absorbance at 450 nm over a 90-s period by using a kinetic microplate reader (Molecular Devices, Sunnyvale, CA).
Nitrite measurements by HPLC
Heparinized blood samples were collected from endotoxemic mice by cardiac puncture. Plasma samples (200 µL) were deproteinized with 400 µL acetonitrile and centrifuged at 3000 rpm for 5 min. Salicylic acid (100 µg/mL) was added to samples as an internal standard. Supernatants were drawn off and evaporated under nitrogen, and 50 µL of extract was reconstituted in 50:50 mobile phase (as detailed below). Nitrite concentration was determined by using an IonPac AS4A-SC ion-exchange column, (250 mm × 4 mm, Dionex) and a mobile phase of water-20% acetonitrile/0.1% sodium chloride-20% acetonitrile (gradient). Samples were injected into the high performance liquid chromatography (HPLC) system at a flow rate of 1.5 mL/min, and detection was by absorbance at 214 nm by using a multiwavelength detector (Agilent Technologies, Mississauga, ON, Canada). Data in chimeric mice were expressed as a percentage of the response in WT mice treated with the same amount of LPS on the same day.
Immunohistochemistry
Samples of lung and colon were removed from leukocyte-iNOS and parenchyma-iNOS mice after injection of saline (n=3) or LPS (30 µg/kg, i.v., n=3) 4 h before killing. Tissues were fixed in 4% paraformaldehyde (pH 7.3) at 4 o C. After washing and cryoprotection in phosphatebuffered saline (PBS) containing 20% sucrose, tissues were embedded, cut on a cryostat (12 µm) and processed for indirect immunofluorescence as previously described (10) . Sections were washed in PBS and incubated with primary antibodies raised against mouse neutrophils (rat antimouse neutrophils, clone 7/4, 1:1000; Serotec Ltd, Kidlington, Oxford, UK) or iNOS (rabbit anti-murine iNOS, N32030, 1:500; Transduction Laboratories, Lexington, KY) for 24 h at 4 o C. Sections were washed and incubated with secondary antibodies (donkey anti-rat Cy3, donkey anti-rabbit Cy3; 1:100; Jackson ImmunoResearch Laboratories, West Grove, PA) for 1 h at room temperature. After further washing, sections were mounted in bicarbonate-buffered glycerol (pH 8.6) and viewed with a Zeiss Axioplan fluorescence microscope. Photographs were taken with a digital camera (Sensys, Photometrics, Tucson, AZ), and digital images were processed by using Corel Draw software (Corel Corp., Ottawa, ON, Canada). Image contrast or brightness was altered as necessary, but the images were not manipulated in any other manner.
Determination of microvascular shear rate
Microvascular hemodynamics were determined by using intravital microscopy of the cremaster muscle in anesthetized mice, according to established techniques (24) . Briefly, 4 h after dosing with LPS, mice were anesthetized with a combination of ketamine and xylazine, and the cremaster muscle exteriorized onto an optically clear viewing pedestal, as previously described (24) . Using an intravital microscope (Axioskop, Carl Zeiss Canada, Calgary, Canada) equipped with a video camera (Panasonic 5100 HS, Osaka, Japan), we identified postcapillary venules with diameters ranging from 25 to 35 µm and measured venular diameter (Dv) on-line from a calibrated video monitor. Centerline red blood cell velocity (V RBC ) was also measured on-line by using an optical doppler velocimeter (Microcirculation Research Institute, Texas A&M University, College Station, Texas), and mean red blood cell velocity (V MEAN ) was determined as V RBC /1.6. Venular wall shear rate (γ) was calculated based on the Newtonian definition: γ = 8 (V MEAN /Dv) (25) .
RESULTS
Confirmation of bone marrow repopulation in chimeric mice
Eight weeks after bone marrow transfer, all four groups of mice were healthy and there were no differences in body weight between the groups (Table 1) . Repopulation of all chimeric mice was tested via flow cytometric analysis of Thy-1 expression on isolated thymocytes. In all chimeric animals, >95% of the thymocytes expressed the congenic marker of the donor bone marrow (Fig.1 ). This finding was observed for both the leukocyte-iNOS mice and the parenchyma-iNOS mice. These analyses confirmed that the original marrow had been predominantly replaced by cells of donor origin.
We analyzed whole blood from mice treated with LPS (30 µg/kg, 4 h) for iNOS expression (Fig.  2) . iNOS was expressed strongly and to the same degree in the blood of WT-intact mice and leukocyte-iNOS chimeras, indicating that the LPS treatment used in these experiments was sufficient to induce expression of iNOS mRNA by circulating leukocytes. No iNOS mRNA was detectable in whole blood from parenchyma-iNOS mice or iNOS -/-BMT mice. These data provided additional evidence that complete bone marrow reconstitution by donor cells had occurred in each of the groups of chimeric mice. As iNOS expression was absent in the blood of parenchyma-iNOS chimeras, this indicated that the original WT marrow had been effectively replaced by iNOS -/-bone marrow. Conversely, in leukocyte-iNOS mice, iNOS expression in blood was comparable with that in WT mice, indicating that the original iNOS-deficient marrow had been completely replaced by WT cells.
iNOS expression in LPS-treated chimeric mice
Following treatment with 10 or 30 µg/kg LPS, iNOS mRNA was detectable in liver, colon, lung, and cremaster muscle from WT mice (data not shown), in accordance with our previous observations (24) . WT-intact mice, that is, animals that had undergone the same radiation and bone marrow transfer as chimeric mice but retained the complete WT genotype, displayed levels of iNOS expression very similar to those in normal WT mice. Conversely, no iNOS was detectable in iNOS -/-BMT mice, that is, mice that had undergone the bone marrow transfer protocol but retained the complete iNOS -/-genotype. To quantitate iNOS expression from all groups in a standardized manner and allow comparison between the groups, iNOS and GAPDH RT-PCR products from these experiments were digitized and relative iNOS expression was determined for multiple mice from all groups.
Expression of iNOS in the lung is shown in Figure 3 . In leukocyte-iNOS mice treated with 10 µg/kg LPS, the ratio of iNOS mRNA to GAPDH mRNA was similar to that observed in WTintact mice, indicating that leukocyte-derived iNOS was a major contributor to total iNOS expression in this response. The level in parenchyma-iNOS mice was <50% of that in WT-intact mice, suggesting that parenchymal cells contributed a smaller component of total iNOS expression in the lung in response to this dose of LPS. In response to 30 µg/kg LPS, iNOS expression was similar in leukocyte-iNOS and parenchyma-iNOS mice, with both chimeric groups displaying approximately 30-40% the level of expression in WT-intact mice.
Expression of iNOS in the colon is shown in Figure 4 . In response to both 10 and 30 µg/kg LPS, the level of iNOS mRNA expression was almost identical in WT-intact mice and parenchymaiNOS animals. Leukocyte-iNOS mice displayed negligible iNOS expression. These data reveal that, in the colon during endotoxemia, most iNOS is derived from parenchymal cells.
The pattern of iNOS expression in the liver of LPS-treated chimeric mice (Fig. 5 ) was similar to that observed in the colon. In response to 10 µg/kg LPS, the ratio of iNOS mRNA to GAPDH mRNA in parenchyma-iNOS mice was 50% of that observed in WT-intact mice. In response to 30 µg/kg LPS, iNOS expression in parenchyma-iNOS mice reached similar levels to that in WTintact mice. In contrast, in leukocyte-iNOS mice at both doses of LPS, iNOS was expressed at markedly lower levels. These findings indicated that, in the liver, iNOS was derived predominantly from resident parenchymal cells, and only a minor component of the iNOS mRNA was leukocyte-derived.
Finally, in the cremaster muscle, the distribution of iNOS expression varied with the dose of LPS used (Fig. 6) . In response to 10 µg/kg LPS, the level of iNOS expression did not differ between leukocyte-iNOS mice and parenchyma-iNOS mice. In both cases, iNOS expression was <50% than that observed in WT-intact mice. In response to 30 µg/kg LPS, the pattern of expression was very similar to that seen in the colon in that minimal iNOS mRNA was detectable in leukocyte-iNOS chimeras, whereas the level of expression in parenchyma-iNOS mice was comparable with that in WT-intact mice. Clearly at the higher dose of LPS, the parenchyma was the predominant source of iNOS expression, whereas, at the 10 µg/kg dose, the leukocyte compartment played a somewhat greater role.
MPO levels in chimeric mice following LPS administration
To determine whether the major involvement of leukocyte-derived iNOS in total lung iNOS expression was associated with a comparable elevation in leukocyte recruitment, we measured MPO levels. Lung MPO data were compared with MPO levels in the colon, in which leukocytederived iNOS contributed only minimally to total iNOS expression. In response to 30 µg/kg LPS in all groups of chimeric mice, the amount of MPO per mg of lung tissue was 20-to 30-fold higher than levels in the colon (Fig. 7) . Comparable differences between the two tissues were observed following treatment with 10 µg/kg LPS (data not shown).
Immunohistochemistry using a specific anti-neutrophil antibody revealed that, in both leukocyteiNOS and parenchyma-iNOS mice after LPS injection, there was a significant increase in neutrophil infiltration (Fig. 8B, 8D) . Furthermore, the amount and distribution of neutrophil infiltration induced by LPS treatment did not differ between the two groups of chimeric mice. In saline-treated parenchyma-iNOS mice (Fig. 8C) there appeared to be a few more basal neutrophils than in the leukocyte iNOS mice (Fig. 8A) , in which only occasional scattered cells were detected. In the colon (not shown), there were very few neutrophils in any group.
Next we used immunohistochemistry to examine iNOS protein expression in the lung. The expression of iNOS protein detected by immunohistochemistry confirmed the results obtained by RT-PCR. As shown in Figure 9B , intense iNOS expression was observed in the lungs of leukocyte-iNOS animals, but this expression was confined to infiltrating cells. In contrast, in the parenchyma-iNOS mice injected with LPS, no iNOS protein was detected (Fig. 9D) . No iNOS was detected in mice from each group treated with saline (no LPS) (Fig. 9A, 9C ). It is important to note that, using immunohistochemistry, we were unable to detect significant iNOS expression in the lungs of LPS-treated parenchyma-iNOS mice (Fig. 9D) or the colon (data not shown) in either group of chimeric animals after LPS treatment. This finding occurred despite the presence of strong RT-PCR products in the lung and colon of parenchyma-iNOS mice.
It is our contention that the iNOS protein in parenchymal tissue is sufficiently diffuse that detection via immunohistochemistry is not possible. Therefore, we measured the end product nitrite as an index of iNOS enzymatic activity in both parenchyma-iNOS and leukocyte-iNOS mice (Fig. 10) . Following LPS treatment (30 µg/kg, 4 h), plasma nitrite in parenchyma-iNOS mice was not different from similarly treated WT mice. In contrast, nitrite levels in leukocyteiNOS mice, in which iNOS activity was limited to the leukocyte compartment, were consistently reduced by ~40% from levels in WT mice. Clearly, the parenchymal-iNOS mice were indeed producing ample iNOS despite the difficulty of detecting expression of iNOS protein via immunohistochemistry.
Microvascular hemodynamics in LPS-treated chimeric mice
To examine the functional importance of the localization of iNOS expression, we studied microvascular hemodynamics in postcapillary venules in the cremaster muscles of LPS-treated chimeric mice (Table 1 ). These data showed that, in this area of the microvasculature, no differences in shear rate were observed between each of the four groups of chimeric mice, including mice in which iNOS was completely absent. This finding indicated that, under the conditions used in this study, iNOS does not play a critical role in regulating microvascular shear rate in the cremaster muscle.
DISCUSSION
The role of iNOS-derived nitric oxide in the sepsis response remains controversial. During sepsis, iNOS can produce high levels of nitric oxide, and may play a role in sepsis-induced hypotension (3, 7) . Furthermore, some evidence indicates that, in the presence of the oxidant superoxide, nitric oxide can react to form the potent cytotoxic oxidant peroxynitrite (8) . In contrast, it has been shown that iNOS can act as an endogenous protective molecule during a wide range of immune-mediated disease processes, including endotoxemia (10, 12-15, 24, 26) . One possible explanation for these conflicting observations of damaging and protective functions for iNOS-derived nitric oxide is that different organs may be affected differently by iNOS, potentially due in part to differing cellular sources and/or levels of iNOS induction between different tissues. The latter is not trivial, as nitric oxide is thought to require coincident expression of the superoxide anion in order to produce peroxynitrite (8, 27) . Leukocytes have the capacity to produce both nitric oxide and superoxide, whereas other cells such as epithelial cells (intestinal and pulmonary), smooth muscle cells, and hepatocytes are less effective producers of superoxide. This unique ability of leukocytes could potentially make the contribution of leukocyte-derived iNOS a key determinant of the role of iNOS in the endotoxemic response.
The present study provides a unique analysis of the separate contributions of iNOS expressed by either leukocytes or parenchymal cells to total iNOS expression during endotoxemia. Use of a chimeric approach has allowed clear distinction between these two sources of iNOS expression. In leukocyte-iNOS mice, leukocytes were the only possible source of iNOS, whereas in the parenchyma-iNOS mice, only the parenchymal compartment (not circulating or infiltrating leukocytes) could express iNOS. Using this approach we could demonstrate that during the early stages of the endotoxemic response, leukocyte-derived iNOS was only a minor contributor to the total iNOS expression by most tissues other than the lung. This was despite the demonstrated ability of circulating leukocytes to express iNOS in response to LPS stimulation. Furthermore, the expression data were supported by indirect analysis of systemic NOS activity, that is, plasma nitrite analysis, which suggested that parenchymal cells were the dominant source of LPSstimulated nitric oxide production. Although our immunohistochemistry detected only iNOS protein in leukocytes, we believe this is due to the more diffuse expression of iNOS in parenchymal cells than in neutrophils. Clearly the immunohistochemistry revealed that a single neutrophil in tissue produces more iNOS than a single parenchymal cell, but, based on our systemic nitrite results, all parenchymal cells combined produce more iNOS than all neutrophils.
It has been appreciated for some time that iNOS can be expressed by a wide range of cell types during various inflammatory responses (3). More recent observations have indicated that circulating leukocytes were also capable of iNOS expression during the sepsis/endotoxemia response (17, 28) . However, the relative contribution of iNOS expressed by circulating leukocytes to total iNOS expression remained unknown. The data indicate that, of the tissues we examined, the lung was unique in that a major component of the total iNOS expression was leukocyte-derived. This observation is most likely accounted for by the dramatic increase in lung leukocyte content that occurs during endotoxemia. The lung is one of the primary sites of leukocyte trapping in endotoxemia (29) . Indeed, the MPO and immunohistochemical analyses from the present study indicate that the relative amount of tissue leukocyte content in the lung is >30-fold higher than that which occurs in the colon during endotoxemia. In light of these observations, the major contribution of leukocyte iNOS to total tissue iNOS in endotoxemic lung is clearly due to the relatively large number of leukocytes present in this tissue.
However, this view does not negate the possibility that leukocytes recruited to the pulmonary microvasculature may respond to this microenvironment by up-regulating iNOS expression to a greater extent than in other vascular beds. Indeed the lung is in greater contact with external stimuli, which may increase the level of iNOS expression in leukocytes present in the lung beyond that induced by the original endotoxin stimulus. This possibility is supported by the fact that many cell types require combined stimulation with two or more mediators for effective iNOS induction (30, 31) . Furthermore, the human lung is one of the few tissues in which continuous iNOS expression has been demonstrated in the absence of an obvious inflammatory response, indicating that the conditions in this tissue promote iNOS induction (32) . Clearly, the contention that the pulmonary microenvironment acts to enhance iNOS expression by leukocytes cannot be discounted. Nevertheless, the fact that we could detect iNOS in circulating cells suggests that a significant amount of iNOS was already being expressed by these cells before being trapped in the lung.
Our mRNA and immunohistochemistry results combined with the chimeric mouse nitrite data provide an important lesson. It may be argued that iNOS protein and/or mRNA is the most relevant end-point to measure in this type of experiment. However, iNOS protein is rarely expressed at sufficiently high levels to be readily detectable. Indeed, most studies, which have shown up-regulation of iNOS protein in vivo, have used extremely strong stimuli, for example live bacteria plus LPS and extended periods of incubation (30, 33) . In contrast, the studies that have demonstrated iNOS induction in circulating leukocytes have readily demonstrated upregulation of iNOS mRNA and nitrate/nitrite production, without showing iNOS protein (17, 28) . Although the possibility exists that mRNA expression does not necessarily reflect an increase in iNOS protein, our own experience has indicated a reasonably close correlation between mRNA and functional results attributable to iNOS expression (24, 34) . Furthermore, leukocytes expressing iNOS mRNA in the absence of detectable protein have been shown to produce nitric oxide and to alter their own functions and that of other cells in a nitric oxidedependent manner (35) . These observations suggest that in both the previous work and the present study, a detectable up-regulation of iNOS mRNA correlates to sufficient iNOS protein to alter physiological function in this cell type.
The contribution of the dose of LPS used to the cellular distribution of iNOS is worthy of consideration. The experiments in this study were all performed at the relatively low doses of either 10 or 30 µg/kg. This dose was chosen as previous experiments have shown that it causes induction of iNOS within 4 h without dramatically affecting microvascular hemodynamics (24) . However, previous experiments indicate that the cell types that induce iNOS in response to LPS treatment vary according to the dose of LPS used. Low-dose endotoxemia (~0.5 mg/kg) has been shown to be effective at rapidly inducing expression of iNOS mRNA and production of nitric oxide metabolites by circulating leukocytes (28, 36) . Alternatively, higher-dose (16 mg/kg) LPS induces detectable expression of iNOS protein in leukocytes, as well as a range of parenchymal cells, such as endothelial cells and hepatocytes (37) . Given these observations, it is conceivable that the cellular distribution of iNOS expression observed following high-dose LPS may differ from that seen in the present experiments. In addition, it is important to note that iNOS expression in humans following exposure to bacterial endotoxin may not follow the same pattern as observed in the current study. Indeed, previous studies have described differences in regulation of iNOS expression between humans and rodents (30, 38) . Nevertheless, the current data do provide novel information on the cellular localization of iNOS in murine endotoxemia.
CONCLUSIONS
We have demonstrated that during the endotoxemic response, the cellular source of iNOS expression varies markedly between tissues. This knowledge should prove valuable in furthering our understanding of the pathophysiological role of iNOS in endotoxemia/sepsis. Table 1 Body weights 8 weeks after bone marrow transfer, and microvascular shear rates 4 after LPS treatment (30 µg/kg), in iNOS chimeric mice. C, D) . After LPS injection, there was a comparable increase in neutrophil infiltration in both leukocyte-iNOS and parenchyma-iNOS mice. In saline-treated parenchyma-iNOS mice, there appeared to be more basal neutrophils than in leukocyte-iNOS mice, where only occasional, scattered cells were detected. Scale bar = 50 µm. 
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